RBC Capital Remains a Hold on Verrica Pharmaceuticals (VRCA)

In a report released on November 7, Gregory Renza from RBC Capital maintained a Hold rating on Verrica Pharmaceuticals (VRCAResearch Report), with a price target of $4.00. The company’s shares closed yesterday at $2.24.

Renza covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Seagen, and Prometheus Biosciences. According to TipRanks, Renza has an average return of -2.3% and a 33.18% success rate on recommended stocks.

Verrica Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $7.50.

See today’s best-performing stocks on TipRanks >>

VRCA market cap is currently $91.23M and has a P/E ratio of -1.40.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Read More on VRCA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More